The widely used prostate-specific antigen (PSA) test, which is the current standard blood test for PCa diagnosis, has been found to be unreliable; fewer than one in three men with an elevated PSA will have PCa11, and the test misses ~15% of tumors12. This evidence concerns the gene KLK3 and posterior cortical atrophy.